Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of Sanofi’s prioritized oncology assets with sintilimab, the leading… Read More
15% Discount Available for LSBC Members. Email membership@lifesciencesbc.ca to get a promo code. Where the Rubber Hits the Road: Implementing Innovation and Access for Patients Where we’ll embrace change, turn… Read More
Using 3D bioprinting to revolutionize tissue testing VoxCell aims to provide a new platform for oncology drug screening. Their tissues are designed to mimic human-like cancer tissues that are used during… Read More
VANCOUVER, BC — Eyam Vaccines and Immunotherapeutics (Eyam), has announced a new licensing agreement for innovative vaccine technologies from the University of British Columbia (UBC), and The James Hutton Institute (JHI). The news comes with the recent development and advancements of new technologies for two novel vaccine vector platforms led by Professor Wilfred Jefferies of Michael Smith Laboratories in Vancouver, Canada, and Dr. Paolo Ribeca at JHI’s Biomathematics and Statistics Scotland in Edinburgh, Scotland.
VANCOUVER – University of British Columbia professor Sudip Shekhar is the first Canadian to receive the Schmidt Science Polymath award, which will grant his team roughly $3 million over a… Read More
